333 results about "Metabolic function" patented technology

The invention relates to the technical field of microorganisms, in particular to application of pediococcus acidilactici ZJUIDS13 in improvement of liver diseases, including improvement of alcoholic liver diseases and improvement of fatty liver diseases related to metabolic dysfunction. The pediococcus acidilactici ZJUIDS13 has relatively strong capability of protecting liver injury induced by alcohol, and can improve the states of liver injury and lipid metabolism disorder caused by high fat diet.

The invention discloses application of a bifidobacterium animalis subspecies F1-7 in preparation of a medicine for preventing or treating sarcopenia, belongs to the technical field of microorganism application, and provides application of the bifidobacterium animalis subspecies F1-7 in preparation of the medicine for preventing or treating sarcopenia. The invention relates to an application of bifidobacterium animalis subspecies F1-7 in preparation of drugs for improving bile acid metabolic function decline caused by sarcopenia. The invention relates to an application of bifidobacterium animalis subspecies F1-7 in preparation of a medicine for improving intestinal flora imbalance caused by sarcopenia. The invention finds that the bifidobacterium animalis subspecies F1-7 can effectively improve the skeletal muscle quality of mice with sarcopenia, improve the condition of tension reduction, regulate intestinal flora, promote bile acid metabolism and further relieve muscular atrophy, and enriches a probiotic library for improving sarcopenia.

Provided herein is a method for the screening of patients with at-risk MASH (metabolic dysfunction-associated steatohepatitis, formerly named nonalcoholic steatohepatitis or NASH). The combination of levels of five circulating markers, i.e. alanine aminotransferase (ALAT), aspartate transaminase (ASAT), platelets, hsa-miR-34a and YKL-40 in a subject, and eventually the age and gender of said subject, allows to accurately identify non-cirrhotic at-risk MASH. The information obtained from the levels of these markers also allows to screen a subject as being eligible to liver biopsy and / or to classify a subject as a receiver or non-receiver of a treatment of MASH and / or to classify a subject as a responder or non-responder of a treatment of MASH.

The present invention relates to methods of treating metabolic dysfunction-associated steatohepatitis (MASH) in a human subject, comprising administering to the subject a therapeutically effective amount of indeglitazar or a pharmaceutically acceptable salt thereof.

The invention belongs to the technical field of biological medicines, and particularly relates to application of beta-hydroxybutyrate in preparation of a medicine for preventing or treating hepatocellular carcinoma. The invention provides an application of beta-hydroxybutyrate in preparation of a medicine for preventing and / or treating hepatocellular carcinoma. The beta-hydroxybutyrate comprises a beta-hydroxybutyrate or a combination of a plurality of beta-hydroxybutyrates. A series of experimental data show that beta-hydroxybutyrate not only can effectively improve fatty degeneration and inflammatory response of hepatocytes, but also can remarkably reduce the risk of occurrence of metabolic dysfunction related hepatocellular carcinoma (HCC), and can inhibit malignant biological characteristics of HCC. The invention provides a powerful scientific basis for the development of novel HCC prevention and treatment medicines, and has a wide clinical application prospect.

The invention provides a novel compound feed for leuciscus waleckii, which comprises the following components: 10 to 30 percent of fish meal, 8 to 12 percent of soybean protein concentrate, 15 to 20 percent of flour, 3 to 6 percent of casein, 0.5 to 2 percent of gelatin, 4 to 6 percent of corn protein powder, 2 to 3 percent of soybean oil, 2 to 3 percent of fish oil, 18 to 24 percent of dextrin, 0.3 to 0.6 percent of mineral substance and vitamin premix, 0.2 to 0.6 percent of choline chloride, 1.5 to 2.5 percent of monocalcium phosphate, 0.05 to 0.12 percent of vitamin C ester, 2.5 to 3.5 percent of microcrystalline cellulose and the balance of water. The non-grain novel protein source defatted tenebrio molitor powder is used for partially replacing the fish meal, and the replacement proportion is 0-60%. The invention further provides a preparation method of the novel compound feed for the leuciscus waleckii, and the obtained feed is used for the leuciscus waleckii and can promote the growth performance, the digestive function, the protein metabolism function, the lipid metabolism function, the immune function and the oxidation resistance of the leuciscus waleckii. The invention provides a theoretical reference for developing a novel non-grain protein source, saving fish meal protein, reducing the feed cost and optimizing the artificial compound feed for the leuciscus waleckii.

The invention discloses a construction method of a metabolism-related fatty liver cancer (MAFLD liver cancer) mouse model, and relates to the technical field of biology. The specific construction method comprises the following steps: feeding a 7-9-week-old mouse with a high-fat and high-sugar diet for 24 weeks, inducing the mouse to form fatty liver, and causing metabolic dysfunction; injecting carbon tetrachloride into the abdominal cavity of the mouse once a week while feeding the mouse with the high-fat and high-sugar diet, and inducing the liver of the mouse to form liver cancer continuously for 24 weeks, so as to construct the MAFLD liver cancer mouse. The mouse liver constructed by the method has metabolic dysfunction, fatty liver and liver cancer lesions, and has extremely high application value in research and development of drugs for researching MAFLD liver cancer pathogenesis and fatty liver related liver cancer in the future.

The invention discloses a preparation method and application of a bovine tongue mucous membrane organoid, and relates to the technical field of organoid separation and culture. The preparation method of the ox tongue mucosa organoid comprises the following steps: treating fetal ox tongue tip tissues with digestive enzymes Dispase I, Collagenase II and Collagenase IV, separating ox tongue mucosa, cutting into pieces, treating again with pancreatin, and sieving to remove tissues and impurities; and continuously culturing by adopting a three-dimensional culture technology-matrigel embedding method and an organoid culture medium to obtain the final ox tongue mucous membrane organoid. The ox tongue mucous membrane organoid prepared by the preparation method disclosed by the invention has normal cell proliferation, differentiation and metabolism functions, and can be stably passaged under an in-vitro culture condition; the method can be widely applied to various related scientific researches such as FMDV infection mechanism research, drug screening and vaccine evaluation.

The invention discloses a traditional Chinese medicine composition for treating fatty liver diseases related to metabolic dysfunction. The traditional Chinese medicine composition is prepared from the following raw material medicines: Qu fructus aurantii, lotus leaves, semen cassiae, gynostemma pentaphylla, rhizoma alismatis, rhodiola rosea, radix salviae miltiorrhizae, pseudo-ginseng and rhizoma atractylodis macrocephalae. The traditional Chinese medicine composition and the traditional Chinese medicine compound preparation disclosed by the invention can improve the blood sugar and blood fat levels of fatty liver diseases related to metabolic dysfunction and improve the metabolic level, are remarkable in clinical curative effect, improve the living quality of patients, have the effects of regulating qi, soothing the liver, tonifying the spleen and removing stasis, slow down liver fibrosis by improving blood sugar and blood fat metabolism, and are quick in curative effect and low in price.

The invention relates to the technical field of hyperbaric oxygen physiotherapy cabins, in particular to a terahertz wave micro hyperbaric oxygen physiotherapy cabin which comprises a cabin body, a door opening is formed in one face of the cabin body, a cabin top is installed at the top of the cabin body, and a door plate is hinged to the interior of the door opening through a hinge; the deep sea volcanic energy stone treatment device comprises a cabin, two groups of bed bodies are arranged in the cabin, the two groups of bed bodies are symmetrically mounted in the cabin, each bed body is of a hollow structure, and a plurality of terahertz wave generation modules are uniformly laid on the upper surface of each bed body through a support. The pelelith-based passive terahertz releaser formed after the pelelith-based passive terahertz releaser is combined with the ceramic matrix can continuously release terahertz waves with the frequency band of 0.1-12 THz, the vibration frequency is consistent with that of human cells, and the terahertz waves with the frequency band can repair biological enzyme and nucleic acid structure deformation caused by free radical attack and age increase through the biological resonance effect, so that the pelelith-based passive terahertz releaser can be used for repairing biological enzyme and nucleic acid structure deformation caused by free radical attack and age increase. The metabolic function is recovered from the cell molecule level, and the defect that a traditional oxygen cabin can only supply oxygen on the surface layer and cannot be deeply repaired is overcome.

The invention provides a microbial ecological interaction mechanism determination method and device, and relates to the technical field of species correlation research. The method comprises the following steps: determining N microorganisms and abundance thereof based on metagenome data of a target environment sample; determining the abundance grade and correlation based on the abundance of the ith microorganism and the jth microorganism; carrying out metabolic function annotation on the i microorganism and the j microorganism based on a reference genome, and calculating a function overlapping ratio; determining a community construction mechanism based on the abundance correlation and the function overlapping ratio; based on the function overlapping difference, determining a function overlapping grade change; and determining the ecological interaction mechanism of the i and j microorganisms according to the information. The method can be used for systematically revealing a species coexistence mechanism and a metabolic interaction relationship thereof in the microbial community.

Provided herein are therapeutic methods of treatment using agonist leptin receptor (LEPR) antibodies, antigen-binding fragments thereof, or compositions comprising the LEPR antibodies or antigen-binding fragments thereof. Such therapeutic methods include treatment for conditions related to metabolic dysfunction, including for example, lipodystrophy, adiposity or obesity, reducing body weight, non-alcoholic fatty liver disease, hyperphagia, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility.

Method for predicting severity of COVID-19 disease resulting from infection with SARS-COV-2 (severe acute respiratory syndrome coronavirus 2). The method uses a high dimensional approach to construct a comprehensive metabolic landscape of immune cells participating in the anti-viral response against SARS-CoV-2. Also encompassed within the invention are novel immune cell subsets exhibiting metabolic dysfunction that could serve as predictive biomarkers for COVID-19 severity or as targets for therapeutic interventions in COVID-19 disease.

The invention discloses application of hesperidin in preparation of a medicine for preventing and / or treating porcine contagious pleuropneumonia, and belongs to the field of biological medicine. The concentration of the hesperidin is 6.25-25 [mu] g / mL, and cell experiments prove that the hesperidin can inhibit cell inflammatory response and reduce expression of inflammatory factors, and can effectively relieve the actinobacillus pleuropneumoniae induced endovascular dermatitis injury by inhibiting activation of CD14 / TLR4-NF [kappa] B P65. Animal experiments prove that the hesperidin can relieve pathological changes and injuries of various tissues and organs after actinobacillus pleuropneumoniae infection, improve weight loss caused by actinobacillus pleuropneumoniae infection, relieve inflammatory response and metabolic dysfunction caused by actinobacillus pleuropneumoniae, and improve the body weight loss caused by actinobacillus pleuropneumoniae. The composition plays a role in protecting organisms infected by actinobacillus pleuropneumoniae. The invention provides a new scientific basis for controlling porcine contagious pleuropneumonia by using natural medicines.

The invention discloses a synthetic microbial agent for treating uranium-contaminated soil and a preparation method of the synthetic microbial agent. The synthetic microbial agent is prepared from the following bacteria: P.adami, P.megatherium, bacillus subtilis, Artobacter volluticus, symbiotic fungi, Aspergillus niger, sulfate reducing bacteria and Shewanella. The symbiotic fungi are mucor lastein, mucor unimingguminum, mucor circinelloides, mucor dense, rhizopus arrhizus and phylum phthochytrium parasitic fungi. The prepared synthetic microbial agent and synthetic microbial embedded balls are applied to uranium-contaminated soil remediation, the key enzyme activity can be effectively improved, the soil metabolism function is enhanced, meanwhile, exchangeable uranium with high ecological risk is converted into stable and low-harm residual uranium, the mobility and bioavailability of uranium in soil are effectively weakened, and the uranium-contaminated soil remediation effect is improved. Therefore, immobilized remediation of uranium is realized, and a good soil uranium fixing effect is achieved.

Provided herein are therapeutic methods of treatment using agonist leptin receptor (LEPR) antibodies, antigen-binding fragments thereof, or compositions comprising the LEPR antibodies or antigen-binding fragments thereof. Such therapeutic methods include treatment for conditions related to metabolic dysfunction, including for example, lipodystrophy, adiposity or obesity, reducing body weight, non-alcoholic fatty liver disease, hyperphagia, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility.

The invention provides a composition for reducing uric acid and relieving gout and a preparation method thereof, and relates to the technical field of products for reducing uric acid and relieving gout. The composition comprises the following raw materials: 18-24 parts of phellinus igniarius, 9-13 parts of sunflower disc small molecule peptide extract, 3-7 parts of corn stigma, 4-6 parts of poria cocos, 2-5 parts of pawpaw, 3-6 parts of liquorice, 2-5 parts of astragalus extract and 3-6 parts of lettuce extract. The preparation method of the sunflower disc small-molecule peptide extract comprises the following steps: carrying out enzymolysis on sunflower disc powder twice, carrying out membrane filtration to obtain a sunflower disc small-molecule peptide solution, reacting the sunflower disc small-molecule peptide solution with chitosan oligosaccharide and transglutaminase, and carrying out freeze drying to obtain the sunflower disc small-molecule peptide extract. Through the proper raw material composition and proportion, the metabolic function can be effectively regulated to promote excretion of uric acid, so that the content of xanthine oxidase and adenosine deaminase in the liver is obviously reduced, the uric acid level is effectively reduced, the intestinal probiotic structure can be stabilized, the immunity is enhanced, the kidney is protected, and the good effects of reducing uric acid and relieving gout are achieved.

The invention relates to the technical field of medical assistance, in particular to a depression risk assessment method and system based on intestinal flora characteristics. The method comprises the following steps: acquiring an individual enteric microorganism sample, performing nucleic acid sequencing on the enteric microorganism sample, and determining abundance data of functional genes related to a neural activity metabolic pathway in enteric microorganisms; carrying out metabolite detection on the intestinal microorganism sample, and determining concentration data of metabolites related to the neural activity metabolic pathway in the intestinal microorganisms; based on the abundance data of the functional genes and the concentration data of the metabolites, data fusion processing is carried out, a neural activity metabolism function spectrum is constructed, and the neural activity metabolism function spectrum is a multi-dimensional feature vector; and inputting the neural activity metabolic function spectrum into a pre-trained risk assessment model, and outputting a depression risk score of the individual. The accuracy and repeatability of evaluation are remarkably improved, and the method has great potential for early screening, dynamic monitoring and personalized health management.

The invention provides a single strain metabolism characteristic chromatogram database of oral key microorganisms in a high-glucose microenvironment and a construction method and application thereof, and belongs to the technical field of oral microbiology. The method comprises the following steps: simulating an intraoral high-glucose microenvironment in vitro; the method comprises the following steps: carrying out standardized single-strain culture on oral key microorganisms, carrying out whole-spectrum metabolism detection (non-targeted liquid chromatography-mass spectrometry (LC-MS) and non-targeted gas chromatography-mass spectrometry (GC-MS) on culture supernatant, and identifying and analyzing metabolism to construct a single-strain metabolism characteristic spectrum database of the oral key microorganisms in a high-glucose microenvironment. The database can be used for source attribution and cross validation of in-vivo metabolome results, and assists in screening key metabolites and key pathways related to high glucose. According to the method, the reliability of metabolite source judgment is improved, the directional influence of high glucose on the flora metabolism function is revealed, the method is standardized, and resources are platformized.

The invention belongs to the technical field of bioengineering and microbiomics, and particularly relates to an acquisition method and application of a specific metabolic substrate of lactobacillus crispatus and application of a specific carbohydrate active enzyme CAZzyme gene and a polysaccharide utilization site (PUL). Genomes of lactobacillus crispatus and lactobacillus inertus are obtained from a public database, gene annotation is carried out on the genomes of the lactobacillus crispatus and the lactobacillus inertus, and a random forest model and a KEGG metabolic pathway diagram are combined to find specific CAZzyme genes, PUL and other genes with metabolic functions of the lactobacillus crispatus; a substrate which only lactobacillus crispatus can metabolize is searched based on the genome difference of the two bacteria, and the ability of the obtained substrate for promoting the growth of lactobacillus crispatus and inhibiting the growth of inert lactobacillus is evaluated through experiments. Growth and reproduction of the lactobacillus crispatus are promoted through the substrates, so that the lactobacillus crispatus accounts for a higher proportion in vagina microecology, the vagina is protected, and reproduction of other unfavorable bacteria is reduced. The assisted reproduction success rate is improved.

This invention provides a method for monitoring and evaluating the risk of pathogenic bacteria transmission in poultry farm feces, belonging to the field of livestock and poultry biosecurity control technology. The method includes evaluating the risk of Salmonella transmission during the poultry physiological cycle, assessing the risk of antibiotic resistance associated with drug administration behavior, and monitoring the function during composting based on microbial community structure and metabolic function. This invention can accurately locate the highest-risk nodes of pathogen contamination and antibiotic resistance evolution during the breeding cycle, solving the problem of inaccurate identification of risk sources in existing technologies and avoiding poultry product contamination due to missed risk assessments. It overcomes the single-dimensional limitation of existing technologies that only detect the quantity of pathogens, comprehensively evaluating pathogen risk from phenotypic, molecular, and functional levels. The assessment results are more in line with the actual biosecurity needs of poultry farming, ultimately reducing the safety risks of poultry product contamination and the spread of antibiotic resistance.

The invention relates to the technical field of pet disease treatment, and discloses a microbial preparation for treating inflammatory bowel disease, which is prepared from the following raw materials in parts by weight: 3 to 5 parts of clostridium palustris microecological preparation, 30 to 35 parts of enzymolysis chicken liver powder, 10 to 15 parts of glutamine, 8 to 10 parts of fructo-oligosaccharide, and 1 to 3 parts of beta-1, 3, 4-trimethyl-1, 3-pentanediol monoisobutyrate. The composition is prepared from the following components in parts by weight: 10 to 15 parts of 1, 3-D-glucan, 39.5 to 40 parts of maltodextrin, 0.2 to 0.5 part of silicon dioxide and 0.5 to 1 part of magnesium stearate. According to the microbial preparation for treating the inflammatory bowel disease, diarrhea symptoms of tested pets can be relieved to different extents by preparing the microbial preparation, the intestinal functions of the pets can be directly improved to different extents compared with those before, and due to the fact that the absorption and metabolism functions of intestinal tracts on nutrient substances are improved, the intestinal tracts can be prevented from being damaged. Therefore, malnutrition of the tested pets caused by diseases is relieved for a long time, the weight of the tested pets is increased to different degrees, and the microbial preparation has a positive effect on the pets suffering from the chronic bowel diseases.

Provided are novel compounds for GIPR, GLP-1R and GCGR. Specifically, provided are GLP-1R / GIPR / GCGR triagonists peptides, and conjugates comprising an Fc fragment and GLP-1R / GIPR / GCGR triagonists peptides. Pharmaceutical compositions comprising these compounds,as well as uses thereof in treating metabolic conditions and disorders, such as diabetes mellitus, type 2 diabetes, obesity, metabolic dysfunction-associated fatty liver disease (MAFLD), non-alcoholic fatty liver disease (NAFLD), metabolic dysfunction-associated steatohepatitis (MASH), and non-alcoholic steatohepatitis (NASH) are also provided.

The present disclosure relates to small molecule or polymer-conjugated MetAP2 inhibitors. The present disclosure also relates to methods for treating a metabolic dysfunction associated with a disease (e.g., cancer) or alleviating at least one symptom of a metabolic dysfunction associated with a disease (e.g., cancer). The present disclosure also relates to methods for treating cancer or alleviating at least one symptom of cancer, comprising administering a combination of a polymer-conjugated MetAP2 inhibitor and at least one second agent, wherein the second agent can induce metabolic dysfunction.

The application discloses an Akkermansia muciniphila branched-chain amino acid metabolism gene nifJ and application thereof in colostrum IgA synthesis, and belongs to the technical field of genetic engineering. The application finds through in-vivo and in-vitro tests that the nifJ is a branched-chain amino acid metabolism gene of the Akkermansia muciniphila, regulates the metabolism process from branched-chain amino acids to branched-chain short-chain fatty acids, and plays a key role in the synthesis of maternal colostrum IgA. The research result of the application is expected to clarify the interaction relationship between the metabolic function of the Akkermansia muciniphila and a host, and reveal the action mechanism of the Akkermansia muciniphila in regulating the synthesis of maternal colostrum IgA, thereby providing a theoretical basis for improving the maternal colostrum IgA and further improving the maternal reproductive performance.

The invention relates to the technical field of biological medicines, and particularly discloses application of ebbeselenium in preparation of a medicine for treating male delayed gonadal hypofunction. After the ebbeselenium is adopted for intervention, the autophagy activity of testicular interstitial cells of old mice is increased, lipid autophagy is enhanced, testosterone synthesis is promoted, the serum testosterone level is remarkably improved, and the symptoms of male delayed hypogonadism (LOH) are effectively relieved; ebbeselenium simultaneously shows a relatively good delaying effect on senescence of a plurality of organs. The ebbeselenium can improve the reproductive capacity, the behavior memory capacity, the athletic capacity and the metabolic function of old mice at the same time, and synergistic and effective treatment of low serum testosterone and LOH complications is achieved. Besides, by enhancing the molecular reduction effect of PRDX1 targeting ATG4B, the ebbeselenium regulates and controls the autophagy pathway of testicular interstitial cells and enhances the functions of the testicular interstitial cells so as to promote synthesis of testosterone, and a new treatment strategy is provided for treatment of LOH.

The invention provides a nano-phase penthorum chinense pursh extract, which is prepared by the following steps: soaking a penthorum chinense pursh medicinal material, decocting, filtering, collecting filtrate, carrying out layering centrifugation to remove precipitate, dialyzing supernate by adopting a dialysis bag with the molecular weight cutoff of 3.5 kDa, and freeze-drying dialysate to obtain the nano-phase penthorum chinense pursh extract. The invention further provides a preparation method and application of the nanometer phase-state penthorum chinense pursh extract. The invention provides an extraction method capable of accurately separating 50-200nm phase-state active components in a nanometer phase-state penthorum chinense pursh extract traditional Chinese medicine. Organic solvents are prevented from being used, and the safety of extracted products is improved; the purity of the target component is improved; the structural integrity of a natural nanometer phase state is kept; the obtained nanometer phase-state extract has the effects of remarkably improving metabolic dysfunction related steatohepatitis and resisting coagulation, is high in separation efficiency, can be completed in 2-3 days, and can be applied on a large scale; the equipment is simple and low in cost.

The invention discloses an application of an aluminum toxicity relieving preparation based on xanthine in environmental remediation, and provides an environmental remediation preparation taking xanthine as a core active component aiming at the problems of plant growth inhibition and ecosystem imbalance in an aluminum polluted environment. Efficient detoxification is realized through double mechanisms of specific chelation with aluminum ions and plant physiological regulation, so that the concentration of the aluminum ions in a water body can be reduced by 48.5%, and aluminum enrichment in a plant body is inhibited; and on the other hand, xanthine obviously reduces accumulation of reactive oxygen species (ROS) induced by aluminum stress by activating a plant anti-oxidation defense system, so that the reproduction rate of the duckweed thalli is increased by 45%, and the biomass is increased by 67%, thereby reversing damage of aluminum toxicity to plant cell structures and metabolic functions. The invention belongs to the technical field of environmental restoration, and particularly relates to application of a xanthine-based aluminum toxicity relieving preparation in environmental restoration.

Despite the high prevalence and serious clinical implications of metabolic associated steatohepatitis (MASH) in patients with type 2 diabetes (T2D), MASH is usually overlooked in clinical practice, due to the lack of accurate biomarkers. The inventors evaluated the ability of plasma large extracellular vesicles (lEVs) to serve as noninvasive biomarkers for the diagnosis of MASH, in particular in T2D patients. Proteomic analysis identified Transferrinreceptor on lEVs (TFRC-lEVs) as associated with MASH. The inventors thus measured TFRC- lEVs on plasma samples from patients included in the derivation cohort. The proportion of patients with TFRC-lEVs concentration > 61 ng / mL was significantly higher in patients with MASH than in those with steatosis. TFRC-lEVs > 61 ng / mL remained associated with MASH after adjustment on either usual laboratory variables, or on the NASH-Test or on the Fibroscan FAST-score. When combining TFRC-lEVs with available methods the population suspected of having MASH was 32% and 29%, versus 22% and 16% for NASH-test or FAST score alone, without decreasing specificity. In conclusion, TFRC-lEVs, a marker of hepatocyte ballooning, is a promising biomarker for MASH. It could be used for patients' screening to enlarge recruitment of patients with MASH in clinical trials.

The invention discloses China-hemp peptide multi-nutrient protein powder with a metabolism improving function, which comprises China-hemp seeds, soybean protein isolate, China-hemp seed protein, chickpea protein, pea protein, China-hemp peptide, rice protein, broad bean protein, mung bean protein and wheat hydrolyzed protein. Wherein the Chinese hemp seeds are 15-25 parts, the soybean protein isolate is 10-20 parts, the Chinese hemp seed protein is 5-15 parts, the chickpea protein is 8-12 parts, the pea protein is 8-12 parts, the Chinese hemp peptide is 8-15 parts, the rice protein is 5-10 parts, the broad bean protein is 5-10 parts, the mung bean protein is 5-10 parts, and the like. According to the present invention, besides the protein nutrition, the small molecule peptide and 10 other nutrients such as Omega3, gamma-linolenic acid, vitamin E and a variety of minerals are contained, such that the complete protein nutrition is provided, and the health-care food is rich in Omega-3 fatty acid, gamma-linolenic acid, vitamin E, potassium, magnesium, zinc and other minerals with different molecular magnitudes extracted from China-hemp seeds, the ten nutrients, a plurality of plant proteins and small molecule peptides have a synergistic effect to jointly form a basis for improving the metabolic function.